Immutep Ltd

YP1B

Company Profile

  • Business description

    Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3’s ability to stimulate the body’s immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

  • Contact

    264 George Street
    Level 32, Australia Square
    SydneyNSW2000
    AUS

    T: +61 283157003

    E: [email protected]

    https://www.immutep.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    44

Stocks News & Analysis

stocks

How I lost all my savings through a poor investment decision

With first timers at risk of poor investment decisions and an interest in speculative stocks, I explore my biggest investing mistake.
stocks

Our view of Nvidia / OpenAI deal

Big AI dreams as firms announce a strategic partnership.
stocks

Chart of the Week: Morningstar’s forecast for CSL’s future

We see gross margin expansion on efficiencies and limited tariff impact

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,059.1029.600.33%
CAC 407,827.4544.57-0.57%
DAX 4023,666.8155.480.23%
Dow JONES (US)46,121.28171.50-0.37%
FTSE 1009,250.4327.110.29%
HKSE26,479.1939.46-0.15%
NASDAQ22,497.8675.62-0.33%
Nikkei 22545,724.2193.900.21%
NZX 50 Index13,153.7927.52-0.21%
S&P 5006,637.9718.95-0.28%
S&P/ASX 2008,769.0031.100.36%
SSE Composite Index3,845.408.24-0.21%

Market Movers